Accuray Incorporated ( (ARAY) ) has released its Q3 earnings. Here is a breakdown of the information Accuray Incorporated presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Accuray Incorporated is a company specializing in radiation therapy solutions, focusing on innovative technologies for oncology and neuro-radiosurgery, and is headquartered in Madison, Wisconsin.
In the third quarter of fiscal 2025, Accuray reported a 12% increase in total net revenue, reaching $113.2 million, alongside a significant reduction in net loss to $1.3 million from $6.3 million in the previous year. The company’s adjusted EBITDA also saw a notable increase to $6.0 million from $1.1 million in the prior year.
Key financial metrics for the quarter include a 16% rise in product revenue and a 9% increase in service revenue. Gross profit improved to $31.6 million, although the gross margin slightly decreased to 27.9%. Operating expenses were reduced by 9%, contributing to the improved financial performance.
Despite a decrease in gross product orders and a lower book-to-bill ratio, Accuray’s cash position strengthened with cash and equivalents rising to $78.8 million. The company maintains a positive outlook, reaffirming its adjusted EBITDA guidance for fiscal year 2025, although it has adjusted its revenue expectations due to tariff impacts.
Looking ahead, Accuray remains focused on executing its strategic initiatives and navigating global challenges, with confidence in its ability to sustain performance and drive growth through its innovative product offerings.